General Area of Claim


Use of Anti-Prolactin Agents to Treat Cancer/Proliferative Conditions
US 7,115,556
Canada 2,328,520
Japan 5,453,355
Japan 5,259,896

Use of Prolactin Receptor Antagonists in Combination with an Agent that Inactivates the HER2/Neu signaling Pathway
US 8,754,031
Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells (Ovarian Cancer Claims)

US 8,648,046

US 8,754,035

Europe 2400979

France 2400979

Germany 2400979

Italy 2400979

United Kingdom 2400979

Australia 2010218261

Japan 5963443

Korea 10-1672401

Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins

US 7,339,027

US 8,304, 381

Japan 4511108

Japan 5221510

Multimeric Ligands with Enhanced Stability

US 7,632,809

Canada 2,483,330

Europe 2385132

France 2385132

Germany 60345826.2

United Kingdom 2385132

Europe 1576097

France 1576097

Germany 60342479.1

United Kingdom 1576097

Use of Prolactin in the Prophylactic Treatment of Cancer

Europe 1959985

France 1959985

Germany 602006009840.5

United Kingdom 1579985

Bi-Functional Cancer Treatment Agents
US 7,201,905

Our Patents

In addition to patents, Prolanta has received orphan designation from the US FDA for the treatment of ovarian cancer, which  provides for seven years of market exclusivity. Oncolix intends to apply for orphan designation in the EU and Japan to treat ovarian cancer, both which provide for 10 years of market exclusivity.

Furthermore, under the US Affordable Care Act in the United States, biologicals such as Prolanta are granted 12 years of market exclusivity.